Teva Pharmaceutical Industries (TEVA) Research Coverage Started at Leerink Swann

Leerink Swann assumed coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research report issued to clients and investors on Tuesday, The Fly reports. The firm set an “underperform” rating on the stock.

Other research analysts have also issued research reports about the company. Gabelli reiterated a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, September 13th. BidaskClub upgraded Teva Pharmaceutical Industries from a “strong sell” rating to a “sell” rating in a research report on Wednesday, September 13th. Cantor Fitzgerald set a $18.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday, December 28th. Zacks Investment Research upgraded Teva Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Finally, Maxim Group reiterated a “hold” rating and set a $15.50 target price on shares of Teva Pharmaceutical Industries in a research report on Thursday, September 14th. Six analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $20.99.

Shares of Teva Pharmaceutical Industries (TEVA) traded up $0.16 during trading hours on Tuesday, reaching $19.11. 17,458,146 shares of the company traded hands, compared to its average volume of 26,530,000. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $38.31. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. The firm has a market cap of $19,280.00, a P/E ratio of -3.26 and a beta of 0.55.

Several large investors have recently added to or reduced their stakes in TEVA. Schwab Charles Investment Management Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 7.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 241,571 shares of the company’s stock valued at $8,025,000 after purchasing an additional 17,116 shares during the period. State Board of Administration of Florida Retirement System grew its holdings in Teva Pharmaceutical Industries by 1.5% during the second quarter. State Board of Administration of Florida Retirement System now owns 42,611 shares of the company’s stock worth $1,416,000 after acquiring an additional 611 shares during the period. Prudential Financial Inc. grew its holdings in Teva Pharmaceutical Industries by 0.9% during the second quarter. Prudential Financial Inc. now owns 77,973 shares of the company’s stock worth $2,590,000 after acquiring an additional 730 shares during the period. Neuberger Berman Group LLC grew its holdings in Teva Pharmaceutical Industries by 7.6% during the second quarter. Neuberger Berman Group LLC now owns 864,749 shares of the company’s stock worth $28,727,000 after acquiring an additional 60,853 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in Teva Pharmaceutical Industries by 21.1% during the second quarter. Principal Financial Group Inc. now owns 124,174 shares of the company’s stock worth $4,125,000 after acquiring an additional 21,658 shares during the period. 51.98% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Teva Pharmaceutical Industries (TEVA) Research Coverage Started at Leerink Swann” was first reported by American Market News and is the property of of American Market News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/02/teva-pharmaceutical-industries-teva-research-coverage-started-at-leerink-swann.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.